PROXY CORNER: Eli Lilly and Co.
Indianapolis-based Eli Lilly and Co. discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
Eli Lilly and Co.
Articles
Lilly shares rise after drugmaker reports solid second quarter
Strong sales and penny-pinching helped Eli Lilly and Co. beat Wall Street’s expectations in the second quarter, leading the company to raise its profit forecast for the year.
Lilly freezes pay for workers, executives
The pay freeze will save $400 million through 2016, said a spokesman for the Indianapolis-based company. Lilly won’t give pay raises to executives, supervisors or most employees. Some bonuses will also be reduced.
Lilly aims potential Alzheimer’s drug at early patients
The trial of 2,100 patients, called Expedition III, will use new measures of cognitive function, such as the ability to do tasks like cooking or driving, or remembering words after a delay.
Lilly drug for Alzheimer’s gets limited Medicare coverage
Lilly officials said they will push ahead with the first-of-a-kind imaging chemical, despite the mostly negative ruling by Medicare officials.
Lilly’s Lechleiter back at helm after health scare
Eli Lilly and Co. Chairman and CEO John Lechleiter is back to full-time work after taking a leave in May to have surgery for a dilated aorta, the company announced Monday morning.
Miami man pleads guilty to $90M Lilly drug heist
Thieves broke into the Connecticut warehouse of Indianapolis-based Eli Lilly and Co. in 2010 by scaling an exterior wall and cutting a hole in the roof. They lowered themselves to the floor and disabled alarms before using a forklift to load pallets of drugs into a getaway vehicle.
Feds mull covering Alzheimer’s test that uses Lilly’s Amyvid
The $3,000 test for the first time accurately identifies the signature brain plaques of the debilitating disease.
Lilly’s experimental diabetes drug helps patients lose weight
Lilly’s drug, if approved, may be a significant competitor to Novo Nordisk A/S’s Victoza, which generated $1.64 billion in 2012.
Lilly’s Zyprexa injection probed by FDA after deaths
Eli Lilly and Co.’s injectable form of the antipsychotic Zyprexa is being investigated by U.S. regulators after two patients died three to four days after receiving the drug.
Drugmakers may face ‘pay for delay’ suits, high court rules
Drug companies like Eli Lilly and Co. can be sued for paying rivals to delay low-cost versions of popular medicines, the U.S. Supreme Court said in a decision that rewrites the rules governing the release of generic drugs.
Lilly to take over development of diabetes drug
Eli Lilly and Co. will pay Canadian drug developer Transition Therapeutics Inc. at least $7 million and up to as much as $247 million to take over the development of a potential diabetes treatment.
Lilly halts trial of experimental Alzheimers drug
The trial ended after participants showed abnormal liver biochemistry, the Indianapolis-based drugmaker said Thursday in a statement.
Most of Indiana’s largest public companies enjoyed strong 2012
Angie’s List turned a profit for the first time in nearly two decades.
Drug sold by Lilly tops Avastin in colon cancer survival study
Patients who got Erbitux together with chemotherapy as a first-line treatment lived about four months longer than those who got Avastin with chemotherapy, according to the 592-person study.
Endowment assets soar $1.2B as Lilly shares climb
Lilly Endowment awarded $230 million in 2012, mostly to Indiana groups. Its fortunes still are largely tied to the value of Eli Lilly and Co. stock, despite an effort to diversify the private foundation’s holdings.
Lilly study: 1 in 5 Alzheimer’s patients misdiagnosed
The study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get Medicare to pay for use of its brain imaging agent Amyvid.
Canada’s Supreme Court won’t hear Lilly appeal on Zyprexa
Eli Lilly claims recent decisions by Canadian courts invalidating 17 drug patents have made the country an outlier among major developed countries.
Lechleiter’s surgery to repair heart goes as planned
Eli Lilly and Co. CEO John Lechleiter underwent a scheduled surgery Monday for a heart defect, and the repair to the aorta is functioning as intended, the Indianapolis-based drugmaker said.
Lilly stops development on cancer drug after failed study
The drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual sales by 2018.